KalVista Pharmaceuticals, Inc. (KALV) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $27.00 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 9, 2026 | Andrew Fein | H.C. Wainwright | $37.00 | +37.0% |
| Nov 5, 2024 | Serge Belanger | Needham | $28.00 | +3.7% |
| Sep 6, 2024 | Andrew Fein | H.C. Wainwright | $20.00 | -25.9% |
| Sep 6, 2024 | Joseph Schwartz | Leerink Partners | $20.00 | -25.9% |
Top Analysts Covering KALV
KALV vs Sector & Market
| Metric | KALV | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.24 | 2.40 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +6.2% | +11475.0% | +17.1% |
| P/E Ratio | -5.82 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $41M | $47M | $55M | 9 |
| 2026-09-30 | $49M | $56M | $64M | 4 |
| 2026-12-31 | $57M | $64M | $74M | 8 |
| 2027-03-31 | $42M | $48M | $55M | 4 |
| 2027-04-30 | $190M | $199M | $208M | 3 |
| 2028-04-30 | $305M | $311M | $317M | 6 |
| 2029-04-30 | $417M | $425M | $434M | 3 |
| 2030-04-30 | $503M | $513M | $523M | 3 |
| 2031-04-30 | $578M | $589M | $601M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.39 | $-0.27 | $-0.02 | 6 |
| 2026-09-30 | $-0.28 | $-0.24 | $-0.20 | 3 |
| 2026-12-31 | $-0.07 | $-0.06 | $-0.05 | 4 |
| 2027-03-31 | $-0.24 | $-0.20 | $-0.17 | 2 |
| 2027-04-30 | $-1.37 | $-1.21 | $-0.89 | 3 |
| 2028-04-30 | $-3.99 | $0.64 | $11.18 | 6 |
| 2029-04-30 | $1.97 | $2.02 | $2.07 | 2 |
| 2030-04-30 | $3.04 | $3.12 | $3.20 | 2 |
| 2031-04-30 | $3.52 | $3.61 | $3.70 | 4 |
Frequently Asked Questions
What is the analyst consensus for KALV?
The consensus among 8 analysts covering KalVista Pharmaceuticals, Inc. (KALV) is Buy with an average price target of $28.50.
What is the highest price target for KALV?
The highest price target for KALV is $37.00, set by Andrew Fein at H.C. Wainwright on 2026-01-09.
What is the lowest price target for KALV?
The lowest price target for KALV is $20.00, set by Joseph Schwartz at Leerink Partners on 2024-09-06.
How many analysts cover KALV?
8 analysts have issued ratings for KalVista Pharmaceuticals, Inc. in the past 12 months.
Is KALV a buy or sell right now?
Based on 8 analyst ratings, KALV has a consensus rating of Buy (2.25/5) with a +6.2% upside to the consensus target of $28.50.
What are the earnings estimates for KALV?
Analysts estimate KALV will report EPS of $-0.27 for the period ending 2026-06-30, with revenue estimated at $47M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.